Novel Adjunctive Therapies for Pompe Disease
庞贝病的新型辅助疗法
基本信息
- 批准号:10351044
- 负责人:
- 金额:$ 10.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectArchitectureAutomobile DrivingAutophagocytosisAutophagosomeBloodBlood - brain barrier anatomyBrainBreathingCardiacCell TherapyChildhoodClinical ResearchClinical TreatmentClinical TrialsComplexDiseaseDistressEnvironmentEnzymesFDA approvedFRAP1 geneFoundationsFunctional disorderFutureGene DeliveryGenesGlucan 1,4-alpha-GlucosidaseGlycogenGlycogen Storage DiseaseGlycogen storage disease type IIGoalsHealthHeart HypertrophyHumanHypoxiaImmune responseImmunohistochemistryImmunosuppressive AgentsInfantInterventionKnowledgeLeadLocationLysosomesMentorsMetabolicMethodsMolecularMotorMotor NeuronsMusMuscleMuscle WeaknessMuscle functionMyocardiumNerveNeurobiologyNeuromuscular DiseasesNeuronal PlasticityNutrientOrganellesOutputPathologyPathway interactionsPatient CarePatientsPhasePhase I Clinical TrialsPhase II Clinical TrialsProcessProteinsProteomicsRecombinant adeno-associated virus (rAAV)RecombinantsRecyclingResearchResearch PersonnelRespirationRespiratory FailureRespiratory MusclesRespiratory TherapyRespiratory distressRespiratory physiologyScientistSecondary toSirolimusSkeletal MuscleTestingTherapeuticTranslatingUniversitiesViral GenesWhole Body PlethysmographyWorkadeno-associated viral vectorcareerclinical caredisease-causing mutationenzyme replacement therapyexperienceexperimental studygallium arsenidegene replacementgene therapyimprovedinfancyinnovationmotor recoverymouse modelneurophysiologynovelnovel therapeuticspreservationpreventrelating to nervous systemrepairedrespiratoryrespiratory disease/disorder therapyskeletalskillsstandard of caretargeted treatment
项目摘要
PROJECT SUMMARY
Candidate & Environment: The short and long-term goals of the candidate are to gain skills, knowledge, and
experience necessary to become a successful independent investigator in gene therapy for neuromuscular
diseases (NMDs) with respiratory pathology, such as Pompe disease. Duke University is the optimal location for
the candidate to achieve these goals with a world-renowned Pompe disease clinical and research center, along
with myology and gene therapy experts, who frequently collaborate and who host monthly research seminars.
Research: Pompe disease is a fatal glycogen storage disease caused by mutations in the gene encoding acid
α-glucosidase (GAA), which is responsible for hydrolyzing lysosomal glycogen. GAA deficiency results in
glycogen accumulation in the lysosomes of muscles (cardiac, skeletal, smooth) and motor neurons. The only
FDA approved treatment is enzyme replacement therapy (ERT) of recombinant human GAA (rhGAA). ERT
effectively treats cardiac muscle glycogen accumulation but cannot completely correct skeletal muscle pathology
due to disrupted autophagy. In addition, ERT cannot cross the blood-brain barrier to treat motor neurons, and
therefore, respiratory failure persists. Thus, to prevent respiratory distress in Pompe patients, there is a need for
therapies that can clear glycogen and repair autophagy in the respiratory muscles and motor neurons. The
overall goal is to identify novel adjunctive therapies to improve respiratory muscle and motor neuron
pathology in Pompe disease. We propose to administer three autophagy activators which can cross the blood-
brain barrier and assess their therapeutic impact on the motor unit of Pompe mice (Gaa-/-). Acute intermittent
hypoxia (AIH), rapamycin, and recombinant adeno-associated virus (rAAV) gene therapy are potential therapies
to treat Pompe disease, which will be evaluated across three aims. Each therapeutic has a unique and
complementary ability to address autophagy, a critical component of Pompe disease cellular therapy, in key
respiratory muscles and motor neurons. (1) Hypoxia is an activator of the autophagosome initiation complex.
Additionally, AIH induces neuroplasticity in respiratory motor neurons in neurogenerative disorders. (2)
Rapamycin is currently administered to Pompe patients as an immune suppressor, however, rapamycin also has
a direct negative impact on master metabolic regulator, mTORC1, thus activating autophagy. (3) rAAV-GAA
provides the deficient enzyme, thereby reducing glycogen and improving lysosome health which is a key to
restoring normal autophagy. In the final aim of this proposal, we will combine rAAV-GAA therapy with AIH and
rapamycin to determine the cumulative effect. Key methods of analysis include neurophysiology to assess neural
output of respiratory nerves, whole body plethysmography to assess respiration, molecular proteomics analysis
for autophagy pathway proteins, and immunohistochemistry to identify cellular architecture of muscle and CNS.
These novel interventions are already used in clinical trials and have the potential to quickly translate to clinical
care in Pompe patients suffering from respiratory distress.
项目摘要
候选人和环境:候选人的短期和长期目标是获得技能,知识,
成为一名成功的神经肌肉疾病基因治疗独立研究者所必需的经验
呼吸道疾病(NMD),如庞贝氏症。杜克大学是
候选人实现这些目标与世界著名的庞贝氏症临床和研究中心,沿着
与肌肉学和基因治疗专家,谁经常合作,谁主持每月的研究研讨会。
研究:庞贝氏症是一种致命的糖原累积病,由编码酸的基因突变引起。
α-葡萄糖苷酶(GAA),负责水解溶酶体糖原。GAA缺乏导致
肌肉(心肌、骨骼肌、平滑肌)和运动神经元溶酶体中的糖原积累。唯一的
FDA批准的治疗是重组人GAA(rhGAA)的酶替代疗法(ERT)。ERT
有效治疗心肌糖原积聚,但不能完全纠正骨骼肌病理
因为自噬被破坏了此外,ERT不能穿过血脑屏障治疗运动神经元,
因此,呼吸衰竭持续存在。因此,为了预防庞贝氏症患者的呼吸窘迫,需要
治疗,可以清除糖原和修复自噬在呼吸肌和运动神经元。的
总体目标是确定新的连续治疗,以改善呼吸肌和运动神经元
庞贝氏症的病理学我们建议注射三种可以穿过血液的自噬激活剂-
脑屏障,并评估其对庞贝氏症小鼠(Gaa-/-)的运动单位的治疗影响。急性间歇性
缺氧(AIH)、雷帕霉素和重组腺相关病毒(rAAV)基因治疗是潜在的治疗方法
治疗庞贝氏症,将在三个目标进行评估。每种治疗方法都有独特的,
互补的能力来解决自噬,庞贝氏症细胞治疗的关键组成部分,
呼吸肌和运动神经元。(1)缺氧是自噬体起始复合物的激活剂。
此外,AIH诱导神经再生障碍中呼吸运动神经元的神经可塑性。(二)
雷帕霉素目前作为免疫抑制剂施用于庞贝氏症患者,然而,雷帕霉素也具有免疫抑制作用。
对主代谢调节因子mTORC 1产生直接的负面影响,从而激活自噬。(3)rAAV-GAA
提供缺乏的酶,从而减少糖原和改善溶酶体健康,这是
恢复正常的自噬在本提案的最终目标中,我们将联合收割机rAAV-GAA治疗与AIH相结合,
雷帕霉素以确定累积效应。分析的关键方法包括神经生理学,以评估神经
呼吸神经输出,全身体积描记法评估呼吸,分子蛋白质组学分析
用于自噬途径蛋白,以及免疫组织化学以鉴定肌肉和CNS的细胞结构。
这些新的干预措施已经用于临床试验,并有可能迅速转化为临床
庞贝氏症患者的护理患有呼吸窘迫。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Angela L. Roger其他文献
Angela L. Roger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Angela L. Roger', 18)}}的其他基金
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 10.57万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 10.57万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 10.57万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 10.57万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 10.57万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 10.57万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 10.57万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 10.57万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 10.57万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 10.57万 - 项目类别:
Research Grant